Weekly Investment Analysts’ Ratings Updates for Cue Biopharma (CUE)

Several brokerages have updated their recommendations and price targets on shares of Cue Biopharma (NASDAQ: CUE) in the last few weeks:

• 8/27/2026 – Cue Biopharma was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/23/2026 – Cue Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/15/2026 – Cue Biopharma was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/13/2026 – Cue Biopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Cue Biopharma news, insider Sumita Ray sold 8,829 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61. Following the transaction, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. This represents a 6.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $169,346.52. Following the transaction, the vice president owned 48,961 shares of the company’s stock, valued at approximately $1,473,236.49. This trade represents a 10.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 72,715 shares of company stock worth $2,041,555 in the last three months. Corporate insiders own 14.56% of the company’s stock.

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.